Micko22 - the cost of treatment to the pt is generally a far cry form the sales revenue of OSL, or any medical device maker.
The May20 prese estimating $25k per device is IMO the cost to the pt, not the amount OSL would receive. Happy to be corrected is there is any solid data showing that.
Of course if that were OSL revenue then that would suggest only 3 sales in 6 months. Therefore I suggest this is not the amount OSL sales the product for.
Ann: First Austria-based treatments utilising the OncoSil device, page-15
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $13.32M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $23.68K | 4.971M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 23118264 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5200224 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |